盘面热点 新华财经北京7月31日电 A股7月收官，今日市场全天震荡调整，三大指数均跌超1%。本月A股三大指 数月线均收涨，其中创业板指本月累计涨超8%，但沪指3600点整数关得而复失。截至收盘，沪指报 3573.21点，跌1.18%，成交8459亿元；深证成指报11009.77点，跌1.73%，成交10901亿元；创业板指报 2328.31点，跌1.66%，成交5444亿元。 板块方面，辅助生殖、液冷IDC、信创、华为昇腾等板块涨幅居前，钢铁、煤炭、有色、影视等板块跌 幅居前。 盘面上，创新药概念反复走强，南新制药等多股涨停；AI应用端全天逆势活跃，易点天下等涨停；AI 硬件股表现分化，液冷服务器概念全天强势，英维克等涨停；下跌方面，钢铁、有色等顺周期方向集体 走弱，安阳钢铁跌超7%。 个股跌多涨少，全市场近4300只股票下跌。 机构观点 巨丰投顾：周四市场震荡运行，软件开发板块涨幅居前。8月A股市场有望延续结构性行情，中报业绩 密集披露与政策持续发力构成主要支撑，业绩确定性高的行业将受青睐。投资者可围绕三大主线展开： 一是消费复苏主线，关注暑期旺季及政策利好驱动的旅游、家电、医疗保健等领域；二是科技创新主 ...

Core Viewpoint - The article discusses the performance and business operations of Haiprui, a leading multinational pharmaceutical company, highlighting its revenue structure and market dynamics, particularly in relation to the depreciation of the Chinese yuan and its impact on overseas revenue [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and operates with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2]. - The company’s main business revenue composition includes: formulations (56.55%), heparin sodium and low molecular weight heparin raw materials (20.25%), CDMO (19.58%), and others (3.63%) [7]. - As of March 31, 2025, Haiprui reported a revenue of 1.394 billion yuan, a year-on-year increase of 1.53%, and a net profit attributable to shareholders of 157 million yuan, up 1.00% year-on-year [7]. Financial Performance - Haiprui's overseas revenue accounts for 93.04% of its total revenue, benefiting from the depreciation of the yuan [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Dynamics - The stock experienced a decline of 1.40% on July 31, with a trading volume of 152 million yuan and a turnover rate of 0.91%, resulting in a total market capitalization of 19.647 billion yuan [1]. - The stock's average trading cost is 11.28 yuan, with recent buying activity observed, although the buying pressure is not strong [6]. - The stock is currently trading between resistance at 13.88 yuan and support at 12.41 yuan, indicating potential for range trading [6]. Institutional Holdings - As of March 31, 2025, Haiprui's top ten circulating shareholders include Hong Kong Central Clearing Limited and Innovation Drug, with increases in their holdings compared to the previous period [8].

截至收盘，沪指跌1.18%，深成指跌1.73%，创业板指跌1.66%。 沪深两市全天成交额1.94万亿，较上个交易日放量917亿。盘面上，市场热点较为凌乱，个股 跌多涨少，全市场超4200只个股下跌。 从板块来看，创新药概念反复走强，南新制药等多股涨停；AI应用端全天逆势活跃，易点天下 等涨停；AI硬件股表现分化，液冷服务器概念全天强势，英维克等涨停；下跌方面，钢铁、有 色等顺周期方向集体走弱，安阳钢铁跌超7%。大金融板块全天低迷，中银证券跌超5%。板块 方面，辅助生殖、液冷IDC、信创、华为昇腾等板块涨幅居前，钢铁、煤炭、有色、影视等板 块跌幅居前。 今日市场全天震荡调整，三大指数均跌超1%。本月市场总体呈现震荡攀升态势，三大指数月 线均收涨，其中 创业板指本月累计涨超8%，沪指3600点得而复失。 ...

本周A股市场有涨有落，医药板块却已连涨数天。7月29日当天，港股通创新药ETF（520880）大涨 5.06%，领涨全市场所有ETF产品。在此气势如虹的背景下，华宝基金"医药版图"珠玉耀眼，优质医药 基金竞相浮现，向市场充分展示了医药投资的魅力。 目前，华宝基金旗下已拥有港股通创新药ETF（520880）、药ETF（562050）及医疗ETF（512170）3只 医药/医疗专业领域内的ETF投资工具，其中港股通创新药ETF（520880）是迄今已上市的唯一被动跟踪 恒生港股通创新药精选指数的ETF产品，药ETF（562050）是国内唯一跟踪中证制药指数的ETF，医疗 ETF（512170）则已成为同主题竞品中规模最大的头部ETF，备受关注，此外，医疗ETF联接基金（A 类：162412；C类：012323）也为场外投资者把握我国医疗产业发展机遇提供了便利。在主动权益投资 领域，华宝大健康（A类：006881；C类：018529）、华宝医药生物（A类：240020；C类：019029）分 别跨越港股、A股，或聚焦A股，正通过深入研判、大力掘金创新药机遇的方式，将投资者引入至医药 发展蓝海、分享投资果实。 坚定把 ...

每日经济新闻 国投证券指出，当前市场结构正从"杠铃策略"向"中间资产"过渡，科技科创领域迎来周期性拐点。 在产业层面，AI（算力）、港股互联网、创新药、新消费、半导体、新能源（车）等新动能相继迎来 各自的周期性拐点，为低估值大盘成长和"中间资产"重回超额有效性提供条件。创业板指得益于估值在 历史30%分位以下且业绩增长与趋势在宽基指数中占据优势，或将成为最为受益的方向。当前新旧动能 转换进入"新胜于旧"阶段，科技科创领域在宏观利率下移放缓和产业政策支持下，正逐步成为市场关注 的核心方向。 科创综指ETF国泰（589630）跟踪的是科创综指（000680），单日涨跌幅可达20%。该指数是上证 科创板综合指数的简称，旨在反映科创板整体市场表现。科创综指选取科创板中所有符合条件的上市公 司作为样本股，行业分布较为均衡，其中半导体、电力设备、机械制造和医药等行业权重占比较高，特 别是半导体行业的比重达到了38%。 没有股票账户的投资者可关注国泰上证科创板综合ETF发起联接A（023733），国泰上证科创板综 合ETF发起联接C（023734）。 注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌幅及历史表现仅 ...

Core Insights - The Shanghai Stock Exchange Science and Technology Innovation Board (STAR Market) indices showed positive performance, with the STAR Growth Index up by 1.8%, the STAR 100 Index up by 1.1%, the STAR Comprehensive Index up by 0.7%, and the STAR 50 Component Index up by 0.1% as of midday close [1]. Index Performance Summary - The STAR 50 ETF tracks the STAR 50 Component Index, which consists of 50 stocks with large market capitalization and good liquidity, primarily in the "hard technology" sector, with over 60% in semiconductors and more than 75% in total for semiconductors, medical devices, software development, and photovoltaic equipment. The index's valuation percentile is at 146.1 times, with a 0.1% increase noted [2]. - The STAR 100 ETF tracks the STAR 100 Index, which includes 100 stocks with medium market capitalization and good liquidity, focusing on small and medium-sized innovative enterprises. The electronics, pharmaceutical biology, and electrical equipment sectors account for over 80% of the index, with a notable increase of 1.1% and a valuation percentile of 244.1 times [2]. - The STAR Comprehensive Index ETF covers all securities in the STAR Market, focusing on core frontier industries such as artificial intelligence, semiconductors, new energy, and innovative pharmaceuticals. The index saw a 0.7% increase, with a valuation percentile of 234.5 times [2]. - The STAR Growth 50 ETF tracks the STAR Growth Index, which consists of 50 stocks with high growth rates in revenue and net profit. The electronics and pharmaceutical biology sectors account for nearly 75% of the index, with a significant increase of 1.8% and a valuation percentile of 234.9 times [2].

Group 1 - The core viewpoint of the article highlights the recent initiatives by the National Healthcare Security Administration (NHSA) to support innovation in pharmaceuticals and medical devices through new pricing policies and mechanisms aimed at fostering genuine and differentiated innovation [1] - NHSA has held two meetings to discuss these new measures, which include the establishment of unified pricing for new medical services and the exploration of a pricing mechanism for newly launched drugs [1] - Since the approval of measures to support high-end medical device innovation by the National Medical Products Administration in June 2025, there has been a clear trend in top-level design favoring innovation in medical devices, with expectations for more supportive policies in the future [1] Group 2 - The Guotai Innovation Drug ETF (517110) tracks the SHS Innovation Drug Index (931409), which selects listed companies involved in the research and production of innovative drugs from the A-share market, covering various fields such as chemical pharmaceuticals, traditional Chinese medicine, and biological products [1] - The index focuses on companies with high research and development investment and innovation capabilities, aiming to reflect the overall performance of China's innovative drug industry, with an emphasis on growth and industry representation [1] - Investors without stock accounts can consider the Guotai CSI Hong Kong-Shenzhen Innovation Drug Industry ETF Initiated Link C (014118) and Guotai CSI Hong Kong-Shenzhen Innovation Drug Industry ETF Initiated Link A (014117) [1]

Market Performance - A-shares showed mixed performance on July 31, with the Shanghai Composite Index down 0.68% and the ChiNext Index slightly up by 0.43, indicating a volatile trading day [1] - AI concept stocks performed strongly, with several hardware stocks like Cambridge Technology and Invech hitting the daily limit, while innovative drug stocks like Kangyuan Pharmaceutical also saw significant gains [1] Sector Analysis - Chemical pharmaceuticals, software development, IT services, and AI-related sectors showed the highest gains, while steel, coal mining, precious metals, and real estate sectors faced the largest declines [2] Institutional Insights - Huatai Securities identified four key trends in the AI large model industry chain, including a shift to token-driven growth, increasing demand for server computing power, a lead of B-end commercialization over C-end consumer products, and healthy competition among domestic and international firms [3] - CITIC Securities noted a clear signal for policy shifts supporting the innovative drug and medical device industries, suggesting potential recovery in valuations and performance for the medical device sector [3] Economic Indicators - The National Bureau of Statistics reported that the manufacturing PMI for July was 49.3, indicating a slight decline of 0.4 percentage points from the previous month, attributed to seasonal production slowdowns and adverse weather conditions [5] - The National Energy Administration announced that the cumulative photovoltaic power generation in the first half of the year reached 559.1 billion kWh, a year-on-year increase of 42.9%, with significant growth in both centralized and distributed photovoltaic installations [6]

另外，钢铁、煤炭、油气、有色金属等周期性板块全线下跌，安阳钢铁(600569)、包钢股份(600010)、 安泰集团跌超5%。(格隆汇) (责任编辑：宋政 HN002) 格隆汇7月31日｜A股三大指数涨跌不一，截至午盘收盘，沪指跌0.68%报3591.26点，深成指跌0.45%， 创业板指涨0.43%，北证50指数涨0.12%。沪深京三市成交额11578亿元，较上日放量556亿元，两市超 3400只个股下跌。 盘面上，辅助生殖概念涨幅居前，共同药业、利德曼(300289)20cm涨停，我国31省将辅助生殖技术纳入 医保；液冷服务器概念全线走强，思泉新材20CM涨停，英维克(002837)、淳中科技等涨停封板；CPO 概念股大涨，汇绿生态、剑桥科技(603083)涨停，中际旭创(300308)、新易盛(300502)均创历史新高；创 新药板块再度活跃，奥翔药业(603229)、康缘药业(600557)等涨停；AI智能体概念集体走强，易点天 下、用友网络(600588)、南兴股份(002757)涨停，百度搜索首页测试开放智能体应用入口。 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判 ...

Core Viewpoint - The article highlights a collective rebound in the technology sector, driven by strong performances from Microsoft and Meta, which have ignited interest in the computing power segment and sustained momentum in innovative pharmaceuticals [2][8]. Market Overview - The A-share market showed mixed performance with the Shanghai Composite Index down by 0.68% and the Shenzhen Component Index down by 0.45%, while the ChiNext Index rose by 0.43% [2]. - The total trading volume in the Shanghai and Shenzhen markets exceeded 1.14 trillion yuan, an increase of 562 billion yuan compared to the previous trading day [3]. Technology Sector Performance - Major technology stocks rebounded, with CPO (Cloud Power Optimization), PCB (Printed Circuit Board), and other computing hardware leading the gains. Concepts related to communication and AI also saw renewed activity [3][9]. - CPO concept stocks experienced significant gains, with companies like Ruijie Networks and Cambridge Technology seeing substantial increases in stock prices, with Cambridge Technology hitting the daily limit [10][13]. Innovative Pharmaceuticals - The innovative pharmaceutical sector remained active, with stocks like Nanxin Pharmaceutical and Qizheng Tibetan Medicine hitting the daily limit, indicating strong investor interest [17]. - A report from CITIC Securities suggests that recent policy signals support the development of innovative drugs and medical devices, indicating potential investment opportunities in the medical device sector [22]. Notable Stock Movements - Industrial Fulian's stock surged over 8%, reaching a historical high with a market capitalization of 704.2 billion yuan, surpassing Changjiang Electric Power [15]. - The article also notes significant gains in weight-loss drug stocks, with companies like Anke Bio and Dezheng Health seeing increases of over 6% [20][21].